The Biomarkers Consortium’s Cancer, Inflammation and Immunity, Metabolic Disorders and Neuroscience Steering Committees are responsible for identifying and moving forward promising pre-competitive biomarkers projects for implementation by the Biomarkers Consortium, as well as overseeing each individual project under its purview. The members of each Steering Committee represent a variety of sectors, including academia, government, industry and not-for-profit/advocacy organizations, and are led by two co-chairs representing two of the following three sectors: academia, government or industry.
| Gary Kelloff, M.D., NIH/NCI, (Co-Chair)
Geoff Oxnard, M.D., Foundation Medicine (Co-Chair) Emmett Schmidt, M.D., Ph.D., Merck (Co-Chair) Alexandre Akoulitchev, Ph.D., Oxford Biodynamics Jeff Allen, Ph.D., Friends of Cancer Research Daniel Auclair, Ph.D., AstraZeneca Christopher Below, Ph.D., Biognosys Michelle Berny-Lang, Ph.D., NCI Donald A. Berry, Ph.D., MD Anderson Cancer Center Vikram Bhadrasain, M.D., NCI Jonathan Blackburn, Ph.D., Sengenics Mohan Bolisetty, Ph.D., Bristol-Meyers Squibb Gary Borzillo, Ph.D., Janssen Anita Boyapati, Ph.D., Regeneron Claudio Carini, Ph.D., Kings College London Hearn Jay Cho, M.D., Ph.D., The Multiple Myeloma Research Foundation Caroline Chung, M.D., MD Anderson (QIBA-RSNA) Steven Cole, NCI Cecile Combeau, Ph.D., Sanofi Ellie Corigliano, Ph.D., GlaxoSmithKline Adam Corner, BioRad Craig Cummings, Ph.D., Genentech DeAunne Denmark, M.D., Ph.D., Somalogic Michelle Douglas, Ph.D., Genentech Jeff Ecsedy, Ph.D., Ikena Oncology Michael Espey, Ph.D., NCI Steven Gendreau, Ph.D., Genentech Giuseppe Giaccone, M.D., Ph.D., Amgen Ida Grundberg, Ph.D., Olink Stanley R. Hamilton, M.D., City of Hope National Medical Center Sean Hanlon, Ph.D., NCI Lyndsay Harris, M.D., NCI Stephanie Hennek, Ph.D., PathAI James Hnatyszyn, Ph.D., Seattle Genetics, Inc. Steffan Ho, M.D., Ph.D., Pfizer Rob Iannone, M.D., Jazz Pharmaceuticals Peter Intile, SITC Taylor Jensen, Ph.D., LabCorp John Jessup, M.D., Institute for Bioscience and Biotechnology Research Maria Jure-Kunkel, Ph.D., Genmab US, Inc. Jayaprakash Karkera, Ph.D., GlaxoSmithKline |
Morten Karsdal, Ph.D., Nordic Bioscience
Ilan (Lanny) Kirsch, M.D., Adaptive Biotechnologies Tracy Lively, Ph.D., NIH/NCI Kate Lyden, Ph.D., VivoSense Derek McCartney, M.S., Biognosys Robert McCormack, Ph.D. Mark Messenbaugh, J.D., SomaLogic Jen Mills, Ph.D., Foundation Medicine Mike Montalto, Ph.D., PathAI Helen Moore, Ph.D., NIH/NCI Larry Nagahara, Ph.D., John’s Hopkins University Tanya Nguyen, Ph.D., Sapient Bioanalytics Michael O’Neal, M.D., BioClinica, Inc. Mariaelena Occhipinti, Ph.D., Radiomics Snehal Patel, Ph.D., Association for Molecular Pathology Reena Philip, Ph.D., FDA/OCE Vladimir Popov, Ph.D., FNLCR/NCI Scott Knowles Pruitt, M.D., Ph.D.,Merck Elizabeth Punnoose, Ph.D., Genentech Anita Reddy, Ph.D., Amgen Henry Rodriguez, Ph.D., NIH/NCI Vanessa Rodrik-Outmezguine, Ph.D., Eli Lilly & Company Marijana Rucevic, Ph.D., Olink Proteomics Amy Kate Sasser, Ph.D., Genmab US, Inc. Julie Schneider Ph.D., FDA/OCE Lawrence Schwartz, M.D., Memorial Sloan Kettering Maggie Scully, Ph.D.,Frederick Natl. Lab. For Cancer Research Alex Snyder, Ph.D., Generate Biomedicines (SITC) Howard Spiegel, Olink Proteomic Magadelena Thurin, Ph.D., NIH/NCI Peter Ujhazy, M.D., Ph.D., NIH/NCI Tamar Uziel, Ph.D., AbbVie Megann Vaughn, M.B.A., LabCorp Tiffany Vines, Olink Proteomics Wim Vos. Ph.D., Radiomics Sean Walsh, Ph.D., Radiomics Tony Wagner, Ph.D., Jazz Pharmaceuticals Christine Ward, Ph.D., Takeda Pharmaceuticals International, Inc. Mike Ward, Ph.D., Alector Mickey Williams, Ph.D., NIH/NCI |